Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Manuel Jesús Cuesta Zurita
With
Genbioma Aplicaciones SL
Universidad Pública de Navarra
This study aims to evaluate the effectiveness of an add-on postbiotic (Pediococcus acidilactici, pA1c®HI) to antipsychotic drugs on metabolic disturbances and psychopathological dimensions in patients diagnosed with first episode psychotic (FEP) or schizophrenia spectrum disorder (SSD).
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of PEP or TEESQ, according to DSM 5 criteria, aged between 18 and 65 years
Having received antipsychotic treatment for at least 8 weeks before starting the study
You may not be if
Inability to give informed consent, lack of a representative or legal guardian capable of giving consent
Intellectual disability
Clinically significant medical condition (congestive heart failure, liver disease, renal failure, acute pancreatitis, cancer undergoing active treatment, HIV, or other immunodeficiency)
Active substance use in the last 3 months (except nicotine)
